The Experts below are selected from a list of 1185 Experts worldwide ranked by ideXlab platform
Yi Wang - One of the best experts on this subject based on the ideXlab platform.
-
establishment and application of a multiple cross displacement amplification combined with nanoparticles based biosensor method for the detection of bordetella pertussis
BMC Microbiology, 2020Co-Authors: Chunting Liu, Ying Liu, Yue Wang, Yi WangAbstract:Bordetella pertussis is the causative agent of pertussis, a respiratory tract infectious disease. Efficient techniques for detection of B. pertussis isolates are important for clinical diagnosis. Multiple cross displacement amplification (MCDA), a novel isothermal amplification based molecular detection method, has been developed to overcome the technical drawback of the current methods in recent years. This aim of this study is to develop a MCDA with Nanoparticles-based Lateral Flow Biosensor (MCDA-LFB) for the detection of B. pertussis. A set of 10 primers based on the pertussis toxin (PT) promoter region sequence of B. pertussis was designed. The B. pertussis-MCDA-LFB assay was successfully established and optimized at 64 °C for reaction of 40 min. The detection limit was determined as 10 fg/reaction of pure DNA, and no cross-reactions to non-B. pertussis strains were observed, based on the specificity validation. The whole operation, ranging from template preparation to result reporting, could be completed within 70 min without requirement of costly equipment. The B. pertussis-MCDA-LFB in clinic sample detection yielded identical positive rates with traditional culture and showed higher sensitivity than conventional PCR. The results of MCDA-LFB are easier to read due to the usage of LFB. The isothermal amplification based MCDA-LFB established in the present study is a specific, sensitive, rapid and economical technique for the detection of B. pertussis.
-
development and clinical validation of multiple cross displacement amplification combined with nanoparticles based biosensor for detection of mycobacterium tuberculosis preliminary results
Frontiers in Microbiology, 2019Co-Authors: Weiwei Jiao, Yi Wang, Guirong Wang, Yacui Wang, Jing Xiao, Lin Sun, Shuan Wen, Tingting Zhang, Hairong Huang, Adong ShenAbstract:Tuberculosis is still a major threat to global public health. Here, a novel diagnosis assay, termed as multiple cross displacement amplification combined with nanoparticle-based lateral flow biosensor (MCDA-LFB), was developed to simultaneously detect IS6110 and IS1081 of Mycobacterium tuberculosis (MTB) in DNA extracted from reference strain H37Rv and clinical samples. The amplification can be finished within 30 min at a fixed temperature (67°C), thus the whole procedure, including rapid template preparation (15 min), isothermal reaction (30 min) and result reporting (2 min), can be completed within 50 min. The limit of detection of multiplex MCDA assay was 10 fg per reaction. By using the multiplex MCDA protocol, cross-reaction with non-mycobacteria and non-tuberculous mycobacteria (NTM) strains was not observed. Among clinically diagnosed TB patients, the sensitivity of liquid culture, Xpert MTB/RIF and multiplex MCDA assay was 42.0% (50/119), 49.6% (59/119), and 88.2% (105/119), respectively. Among culture positive samples, the sensitivity of Xpert MTB/RIF and multiplex MCDA assay was 86.0% (43/50) and 98.0% (49/50), respectively. Among culture negative samples, the sensitivity of Xpert MTB/RIF and multiplex MCDA assay was 23.2% (16/69) and 81.2% (56/69), respectively. The specificity was 100% (60/60) for Xpert MTB/RIF and 98.3% (59/60) for multiplex MCDA. Therefore, the multiplex MCDA assay for MTB detection is rapid, sensitive and easy to use and may be a promising test for early diagnosis of TB.
-
development of a multiple cross displacement amplification combined with nanoparticles based biosensor assay to detect neisseria meningitidis
Infection and Drug Resistance, 2019Co-Authors: Chunting Liu, Ying Liu, Yue Wang, Yi WangAbstract:Background Neisseria meningitidis is a leading pathogen of meningococcal disease in humans worldwide. Multiple cross displacement mplification (MCDA) combined with nanoparticles-based lateral flow biosensor (MCDA-LFB) has been reported for the rapid detection of several bacterial pathogens in recent years. Here, therefore we developed an MCDA-LFB assay for the rapid detection of N. meningitis. Methods A set of 10 primers specifically to recognize 10 different regions of the ctrA gene of N. meningitidis were designed. MCDA was developed and combined with a LFB to detect the ctrA gene of N. meningitidis. The reaction time and temperature condition for the MCDA-LFB were optimized and then the MCDA-LFB was applied to detect the DNA from clinical samples. Results MCDA-LFB assay was successfully established for the detection of N. meningitidis based on the ctrA gene. The MCDA assay was optimized at 64°C for only 35 mins and the products of amplification were directly sensed by LFB. The whole operation, including DNA template preparation (~20 mins), MCDA reaction (35 mins) and results interpretation (~2 mins) could be finished in no more than 60 mins. The detection limit was as low as 10 fg/reaction (around 3 CFUs/reaction) of pure N. meningitidis DNA, with no cross-reaction with other bacterial DNA. Conclusion The MCDA-LFB techniques developed in the present study are an effective tool for the rapid detection of N. meningitidis, especially in resource-poor countries in meningococcal disease epidemic period.
-
rapid detection of brucella spp and elimination of carryover using multiple cross displacement amplification coupled with nanoparticles based lateral flow biosensor
Frontiers in Cellular and Infection Microbiology, 2019Co-Authors: Ying Liu, Chunting Liu, Yue Wang, Ming Wang, Yi WangAbstract:Brucella spp. is capable of causing disease in a range of animal hosts, and human brucellosis is regarded as a life-threating disease. A novel isothermal amplification technique, termed multiple cross displacement amplification (MCDA), was employed for detecting all Brucella species strains. Brucella-MCDA targets the Bscp31 gene (Brucella species-specific gene) to specifically design a set of ten primers. The Brucella-MCDA can be coupled with nanoparticles-based lateral flow biosensor (LFB) for highly specific, simple, rapid and visual detection of Brucella-specific amplicons. Using the protocol, a MCDA amplification followed by 2-min LFB resulted in visualization of DNA products trapped at the LFB test line. Various species of Gram-positive and Gram-negative strains are applied for optimizing and evaluating the target assay. Optimal MCDA condition is found to be 63°C for 40 min, with detection limits at 10 fg of templates in the pure cultures. The specificity of MCDA-LFB technique is of 100%, and no cross-reactions to non-Brucella strains are observed according to the specificity examination. Furthermore, dUTP and AUDG enzyme are added into the MCDA reaction mixtures, which are used for removing false-positive amplification generating from carryover contamination. Thus, 20 min for rapid template extraction followed by AUDG digestion (5 min), MCDA (40 min) combined with LFB detection (2 min) resulted in a total assay time of approximately 70 min. In sum, Brucella-MCDA-LFB technique is a rapid, simple, reliable and sensitive method to detect all Brucella species strains, and can be used as potential screening tool for Brucella strains in various laboratories.
-
Rapid Detection of Brucella spp. and Elimination of Carryover Using Multiple Cross Displacement Amplification Coupled With Nanoparticles-Based Lateral Flow Biosensor
Frontiers Media S.A., 2019Co-Authors: Ying Liu, Chunting Liu, Yue Wang, Ming Wang, Yi WangAbstract:Brucella spp.is capable of causing disease in a range of animal hosts, and human brucellosis is regarded as a life-threating disease. A novel isothermal amplification technique, termed multiple cross displacement amplification (MCDA), was employed for detecting all Brucella species strains. Brucella-MCDA targets the Bscp31 gene (Brucella species-specific gene) to specifically design a set of 10 primers. The Brucella-MCDA can be coupled with nanoparticles-based lateral flow biosensor (LFB) for highly specific, simple, rapid, and visual detection of Brucella-specific amplicons. Using the protocol, a MCDA amplification followed by 2 min LFB resulted in visualization of DNA products trapped at the LFB test line. Various species of Gram-positive and Gram-negative strains are applied for optimizing and evaluating the target assay. Optimal MCDA condition is found to be 63°C for 40 min, with detection limits at 10 fg of templates in the pure cultures. The specificity of MCDA-LFB technique is of 100%, and no cross-reactions to non-Brucella strains are observed according to the specificity examination. Furthermore, dUTP and AUDG enzyme are added into the MCDA reaction mixtures, which are used for removing false-positive amplification generating from carryover contamination. Thus, 20 min for rapid template extraction followed by AUDG digestion (5 min), MCDA (40 min) combined with LFB detection (2 min) resulted in a total assay time of ~70 min. In sum, Brucella-MCDA-LFB technique is a rapid, simple, reliable, and sensitive method to detect all Brucella species strains, and can be used as potential screening tool for Brucella strains in various laboratories
Robert C. Briggs - One of the best experts on this subject based on the ideXlab platform.
-
dysregulated expression of myeloid nuclear differentiation antigen MNDA in mds possible role in trail induced apoptosis
Blood, 2005Co-Authors: Robert C. Briggs, Keith Shults, Leanne Flye, Madan Jagasia, Stacey Goodman, Sara A Mcclintocktreep, Fouad Boulos, James W Jacobberger, Greg StelzerAbstract:Abstract A reduced level of MNDA expression has been reported with gene expression profiling in both sporadic and familial MDS. We undertook studies to evaluate MNDA protein expression in MDS, and its possible functional significance. Patients (n=7) clinical histories, lab data, cytogenetics, and morphology were reviewed blinded to study results to confirm diagnoses. Patients had Refractory Cytopenia with Multilineage Dysplasia (n=6) or Refractory Anemia with Excess Blasts-1 (n=1)(WHO). Patients lacking primary marrow disease (n=5) were used as controls. Samples were assessed with multiparametric flow cytometry (MPFC) for CD45 antigen density, log side scatter, CD34, CD71, and MNDA (using a specific rat monoclonal antibody) with an FC500 (Beckman-Coulter) flow cytometer, and analyzed with Winlist 5.0 and ModFitLT 3.0 (Verity Software) using published methods and ECFI-generated algorithms. Analyses were blinded to clinical results. Immunohistochemistry (IHC) for MNDA was performed using the same antibody and published methods. Both MPFC and IHC demonstrated MNDA expression in MDS predominantly in granulocyte-macrophage (G-M) progenitors, similar to controls. G-M progenitors in MDS demonstrated reduced MNDA protein expression compared to controls, with 3 patterns: uniform reduced MNDA protein, a mix of normal and absent MNDA protein, or a mix of reduced and absent MNDA protein. We interpret the normal expression in some cases as consistent with presence of a mixture of normal and MDS cells, while the mix of reduced and absent expression may represent clonal evolution of MDS. To evaluate possible functional significance of MNDA expression we used stable K562 clones that express ectopic MNDA protein via retroviral transduction. Parental K562 cells lack MNDA expression. Compared to parental K562, ectopic expression of MNDA failed to protect cells from intrinsic path apoptosis induced by genotoxic agents (mechlorethamine, etoposide, cisplatin) or H2O2. Apoptosis was evaluated by morphology, TUNEL assay, trypan blue exclusion, and phosphorylation of Histone H2B at serine 14 (a specific marker of apoptosis). In sharp contrast, ectopic MNDA expression provided marked protection of cells from extrinsic path apoptosis induced by TRAIL (TNF-related apoptosis inducing ligand) exposure. Disordered apoptosis is hypothesized to be a factor in MDS pathogenesis. Our results indicate MNDA promotes viability in myeloid progenitors, and its down-regulation in MDS might relate to the G-M progenitor sensitivity to TRAIL-induced apoptosis that has been reported in MDS.
-
variable expression of human myeloid specific nuclear antigen MNDA in monocyte lineage cells in atherosclerosis
Journal of Cellular Biochemistry, 2005Co-Authors: Robert C. Briggs, James B Atkinson, Roberto N MirandaAbstract:MNDA (human myeloid nuclear differentiation antigen) is expressed in specific lineages of hematopoietic cells and most notably at high levels in macrophages at sites of inflammation. MNDA and related proteins appear to modulate the activity of transcription factors and in some cases have a role in mediating cell death. The expression of MNDA was characterized in normal and diseased human aorta. MNDA positive cells double labeled for CD68 in all tissue examined. Twenty percent of normal aortas were negative or contained rare MNDA positive cells while other normal aorta contained more frequent positive cells. In atherosclerotic aorta, the number of MNDA positive cells increased with progression of disease. In normal and early lesions, MNDA positive cells adjacent to the endothelium generally displayed a strong MNDA reactivity associated with small amount of CD68 reactive cytoplasm. In the same sections, MNDA positive cells at increasing distances from the endothelium displayed lower MNDA reactivity and were associated with larger amounts of CD68 reactive cytoplasm. Foam cells in fatty streaks exhibited MNDA reactivity that ranged from strong to weak or negative. In advanced lesions, cells in the shoulder and those in fibrous tissue surrounding an atheroma were highly reactive for MNDA. However, only a fraction of the CD68 positive foam cells near the lipid core under the cap and shoulder contained MNDA reactivity. The variation in MNDA expression appeared to change with phenotypic specialization of monocytes in atherosclerosis consistent with its association with inflammation and suspected roles in regulating gene expression or in mediating cell death.
-
myeloid nuclear differentiation antigen MNDA protein expression in myelodysplastic syndrome mds is reduced in maturing myeloid cells
Blood, 2004Co-Authors: Keith Shults, David R Head, Leanne Flye, Madan Jagasia, Stacey Goodman, Sara A Mcclintocktreep, Fouad Boulos, James W Jacobberger, Greg Stelzer, Robert C. BriggsAbstract:Expression of the human MNDA protein is restricted to hematopoietic cells, and occurs at uniformly high level only in the normal granulocyte/monocyte lineage. Myeloblasts and all later stages of the lineage express MNDA, while stem cells do not (Hum Pathol1999;30:1040). Gene expression analyses of MDS cases have shown that MNDA mRNA is significantly down regulated in familial MDS and in high-risk sporadic MDS cases (Blood2000;100:3553 and Leukemia2004;18:449). We evaluated MNDA protein expression in patients with MDS. Methods: We directly conjugated Alexa 488 (Molecular Probes) to a rat monoclonal antibody specific for MNDA for use in multiparameter cytometric analysis with CD45/CD34 and DRAQ5 (DNA content). Patients’ (n=17) clinical histories, laboratory data, cytogenetics, and morphology were reviewed for confirmation of diagnoses and blinded to study results. Patients lacking primary marrow disease (n=9) were used as controls. Analysis was performed using Winlist 5.0 software (Verity Software) with DDE links to ModFitLT 3.0 using modifications of published methods along with Esoterix Center for Innovation generated algorithms. Analyses were blinded to clinical results. Results: The normal dataset revealed MNDA expression in expected cell populations, with only a small subset of CD34+ cells exhibiting MNDA (7.5% on average). Expression of MNDA protein in maturing myeloid forms in normals was consistently greater than in MDS samples (MFI=802 vs. 569 in MDS; MFI=mean fluorescence intensity defined by the linear mean of each population). Six of 17 MDS cases displayed greater than 10% maturing myeloid forms lacking MNDA protein expression (never observed in normals). The % MNDA+/CD34+ cells was identical in the two datasets (7.5% in normal vs. 7.6% in MDS). Discussion: Our results suggest that MNDA protein expression in MDS patients follows a pattern similar to that in gene expression analyses. We additionally demonstrate that MNDA protein expression at the cellular level is variable in MDS, versus uniform expression in normals; parallel data for MNDA message expression at the cellular level is not available. The finding of MNDA-negative myeloid forms in MDS may have diagnostic utility, and may provide insight into both impaired myeloid differentiation in MDS and the biologic role of MNDA.
-
immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic b lymphocytes
Human Pathology, 1999Co-Authors: Robert C. Briggs, Roberto N Miranda, Keith Shults, Marsha C Kinney, Roy A Jensen, John B CousarAbstract:The human myeloid cell nuclear differentiation antigen (MNDA) is a nuclear antigen known to be expressed in mature myelomonocytic cell lines. An extensive immunocytochemical evaluation of fixed tissues confirmed MNDA expression in normal maturing granulocytes and monocytes and in acute nonlymphocytic leukemias and chronic myelogenous leukemia. MNDA was not detected in normal tissue histiocytes but was found in activated macrophages and foreign body giant cells associated with inflammation. Flow cytometric cell sorting of normal bone marrow established that MNDA is initially expressed in myeloid blast cells. Examination of lymphoid tissues showed a low level of expression in a population of normal mande B lymphocytes but not in germinal center cells or plasma cells. A subset of B cell neoplasms expressing MNDA included hairy cell leukemia, parafollicular (monocytoid) B cell lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma. Cell sorting of normal bone marrow showed MNDA expression in CD20+/CD10-/CD5- B cells. MNDA was not detected in other normal bone marrow or all other nonhematopoietic cells. The hematopoietic cell-specific pattern of MNDA expression was elucidated through a comprehensive analysis of normal and neoplastic tissues, and the results provide further evidence of the coexpression of B- and myeloid cell markers in neoplastic B cells and identify a normal B cell population that might be related to the cell of origin of a subset of B cell neoplasms.
-
Human hematopoietic cell specific nuclear protein MNDA interacts with the multifunctional transcription factor YY1 and stimulates YY1 DNA binding
Journal of cellular biochemistry, 1998Co-Authors: Jingping Xie, Judith A. Briggs, Robert C. BriggsAbstract:The human myeloid nuclear differentiation antigen, MNDA, is expressed only in myelomonocytic and a subset of B lymphoid hematopoietic cells. MNDA is uniformly distributed throughout the interphase cell nucleus and associates with chromatin, but does not bind specific DNA sequences. We recently demonstrated that MNDA binds nucleolin and nucleophosmin/NPM/B23 and both of these nuclear proteins bind the ubiquitous zinc finger transcription factor YY1. Investigations of the possible effect of MNDA on the interaction between YY1 and NPM, showed that MNDA bound YY1 directly under both in vitro and in vivo conditions. The MNDA-YY1 interaction enhanced the affinity of YY1 for its target DNA and decreased its rate of dissociation. The N-terminal half (200 amino acids) of MNDA was sufficient for maximum enhancement of YY1 DNA binding and a portion of this sequence was responsible for binding YY1. MNDA participated in a ternary complex with YY1 and the YY1 target DNA element. The results show that MNDA affects the ability of YY1 to bind its target DNA sequnce and that MNDA participates in a ternary complex possibly acting as a cofactor to impart lineage specific features to YY1 function. J. Cell. Biochem. 70:489–506, 1998. © 1998 Wiley-Liss, Inc.
Praveen Thokala - One of the best experts on this subject based on the ideXlab platform.
-
multicriteria decision analysis to support health technology assessment agencies benefits limitations and the way forward
Value in Health, 2019Co-Authors: Rob Baltussen, Praveen Thokala, Kevin Marsh, Vakaramoko Diaby, Hector Castro, Irina Cleemput, Martina Garau, Georgi Iskrov, Alireza Olyaeemanesh, Andrew J MirelmanAbstract:Abstract Objective Recent years have witnessed an increased interest in the use of multicriteria decision analysis (MCDA) to support health technology assessment (HTA) agencies for setting healthcare priorities. However, its implementation to date has been criticized for being “entirely mechanistic,” ignoring opportunity costs, and not following best practice guidelines. This article provides guidance on the use of MCDA in this context. Methods The present study was based on a systematic review and consensus development. We developed a typology of MCDA studies and good implementation practice. We reviewed 36 studies over the period 1990 to 2018 on their compliance with good practice and developed recommendations. We reached consensus among authors over the course of several review rounds. Results We identified 3 MCDA study types: qualitative MCDA, quantitative MCDA, and MCDA with decision rules. The types perform differently in terms of quality, consistency, and transparency of recommendations on healthcare priorities. We advise HTA agencies to always include a deliberative component. Agencies should, at a minimum, undertake qualitative MCDA. The use of quantitative MCDA has additional benefits but also poses design challenges. MCDA with decision rules, used by HTA agencies in The Netherlands and the United Kingdom and typically referred to as structured deliberation, has the potential to further improve the formulation of recommendations but has not yet been subjected to broad experimentation and evaluation. Conclusion MCDA holds large potential to support HTA agencies in setting healthcare priorities, but its implementation needs to be improved.
-
multiple criteria decision analysis for health care decision making emerging good practices report 2 of the ispor mcda emerging good practices task force
Value in Health, 2016Co-Authors: Kevin Marsh, Zoltán Kaló, Praveen Thokala, Rob Baltussen, Meindert Boysen, Filip Mussen, Stuart Peacock, Maarten Joost Ijzerman, Thomas Lonngren, John B WatkinsAbstract:Health care decisions are complex and involve confronting trade-offs between multiple, often conflicting objectives. Using structured, explicit approaches to decisions involving multiple criteria can improve the quality of decision making. A set of techniques, known under the collective heading multiple criteria decision analysis (MCDA), are useful for this purpose. In 2014, ISPOR established an Emerging Good Practices Task Force. An earlier task force report defined MCDA, provided examples of its use in health care, described the key steps, and provided an overview of the principal methods of MCDA. This second task force report provides emerging good-practice guidance on the implementation of MCDA to support health care decisions, including a checklist to support the design, implementation, and review of an MCDA; guidance to support the implementation of the checklist, the order in which the steps should be implemented, and incorporating budget constraints into an MCDA; an overview of the skills and resources required to implement MCDA, including the available software; and future research directions.
-
multiple criteria decision analysis for health care decision making an introduction report 1 of the ispor mcda emerging good practices task force
Value in Health, 2016Co-Authors: Praveen Thokala, Zoltán Kaló, Nancy Devlin, Kevin Marsh, Rob Baltussen, Meindert Boysen, Thomas Longrenn, Filip Mussen, Stuart Peacock, John B WatkinsAbstract:Health care decisions are complex and involve confronting trade-offs between multiple, often conflicting, objectives. Using structured, explicit approaches to decisions involving multiple criteria can improve the quality of decision making and a set of techniques, known under the collective heading multiple criteria decision analysis (MCDA), are useful for this purpose. MCDA methods are widely used in other sectors, and recently there has been an increase in health care applications. In 2014, ISPOR established an MCDA Emerging Good Practices Task Force. It was charged with establishing a common definition for MCDA in health care decision making and developing good practice guidelines for conducting MCDA to aid health care decision making. This initial ISPOR MCDA task force report provides an introduction to MCDA - it defines MCDA; provides examples of its use in different kinds of decision making in health care (including benefit risk analysis, health technology assessment, resource allocation, portfolio decision analysis, shared patient clinician decision making and prioritizing patients’ access to services); provides an overview of the principal methods of MCDA; and describes the key steps involved. Upon reviewing this report, readers should have a solid overview of MCDA methods and their potential for supporting health care decision making.
-
multiple criteria decision analysis for health technology assessment
Value in Health, 2012Co-Authors: Praveen Thokala, Alejandra DuenasAbstract:Abstract Objectives Multicriteria decision analysis (MCDA) has been suggested by some researchers as a method to capture the benefits beyond quality adjusted life-years in a transparent and consistent manner. The objectives of this article were to analyze the possible application of MCDA approaches in health technology assessment and to describe their relative advantages and disadvantages. Methods This article begins with an introduction to the most common types of MCDA models and a critical review of state-of-the-art methods for incorporating multiple criteria in health technology assessment. An overview of MCDA is provided and is compared against the current UK National Institute for Health and Clinical Excellence health technology appraisal process. A generic MCDA modeling approach is described, and the different MCDA modeling approaches are applied to a hypothetical case study. Results A comparison of the different MCDA approaches is provided, and the generic issues that need consideration before the application of MCDA in health technology assessment are examined. Conclusions There are general practical issues that might arise from using an MCDA approach, and it is suggested that appropriate care be taken to ensure the success of MCDA techniques in the appraisal process.
-
multiple criteria decision analysis for health technology assessment
Value in Health, 2012Co-Authors: Praveen Thokala, Alejandra DuenasAbstract:Abstract Objectives Multicriteria decision analysis (MCDA) has been suggested by some researchers as a method to capture the benefits beyond quality adjusted life-years in a transparent and consistent manner. The objectives of this article were to analyze the possible application of MCDA approaches in health technology assessment and to describe their relative advantages and disadvantages. Methods This article begins with an introduction to the most common types of MCDA models and a critical review of state-of-the-art methods for incorporating multiple criteria in health technology assessment. An overview of MCDA is provided and is compared against the current UK National Institute for Health and Clinical Excellence health technology appraisal process. A generic MCDA modeling approach is described, and the different MCDA modeling approaches are applied to a hypothetical case study. Results A comparison of the different MCDA approaches is provided, and the generic issues that need consideration before the application of MCDA in health technology assessment are examined. Conclusions There are general practical issues that might arise from using an MCDA approach, and it is suggested that appropriate care be taken to ensure the success of MCDA techniques in the appraisal process.
John B Watkins - One of the best experts on this subject based on the ideXlab platform.
-
multiple criteria decision analysis for health care decision making emerging good practices report 2 of the ispor mcda emerging good practices task force
Value in Health, 2016Co-Authors: Kevin Marsh, Zoltán Kaló, Praveen Thokala, Rob Baltussen, Meindert Boysen, Filip Mussen, Stuart Peacock, Maarten Joost Ijzerman, Thomas Lonngren, John B WatkinsAbstract:Health care decisions are complex and involve confronting trade-offs between multiple, often conflicting objectives. Using structured, explicit approaches to decisions involving multiple criteria can improve the quality of decision making. A set of techniques, known under the collective heading multiple criteria decision analysis (MCDA), are useful for this purpose. In 2014, ISPOR established an Emerging Good Practices Task Force. An earlier task force report defined MCDA, provided examples of its use in health care, described the key steps, and provided an overview of the principal methods of MCDA. This second task force report provides emerging good-practice guidance on the implementation of MCDA to support health care decisions, including a checklist to support the design, implementation, and review of an MCDA; guidance to support the implementation of the checklist, the order in which the steps should be implemented, and incorporating budget constraints into an MCDA; an overview of the skills and resources required to implement MCDA, including the available software; and future research directions.
-
multiple criteria decision analysis for health care decision making an introduction report 1 of the ispor mcda emerging good practices task force
Value in Health, 2016Co-Authors: Praveen Thokala, Zoltán Kaló, Nancy Devlin, Kevin Marsh, Rob Baltussen, Meindert Boysen, Thomas Longrenn, Filip Mussen, Stuart Peacock, John B WatkinsAbstract:Health care decisions are complex and involve confronting trade-offs between multiple, often conflicting, objectives. Using structured, explicit approaches to decisions involving multiple criteria can improve the quality of decision making and a set of techniques, known under the collective heading multiple criteria decision analysis (MCDA), are useful for this purpose. MCDA methods are widely used in other sectors, and recently there has been an increase in health care applications. In 2014, ISPOR established an MCDA Emerging Good Practices Task Force. It was charged with establishing a common definition for MCDA in health care decision making and developing good practice guidelines for conducting MCDA to aid health care decision making. This initial ISPOR MCDA task force report provides an introduction to MCDA - it defines MCDA; provides examples of its use in different kinds of decision making in health care (including benefit risk analysis, health technology assessment, resource allocation, portfolio decision analysis, shared patient clinician decision making and prioritizing patients’ access to services); provides an overview of the principal methods of MCDA; and describes the key steps involved. Upon reviewing this report, readers should have a solid overview of MCDA methods and their potential for supporting health care decision making.
Yan Wang - One of the best experts on this subject based on the ideXlab platform.
-
rapid sensitive and reliable detection of klebsiella pneumoniae by label free multiple cross displacement amplification coupled with nanoparticles based biosensor
Journal of Microbiological Methods, 2018Co-Authors: Yi Wang, Weiqiang Yan, Yan WangAbstract:Abstract Klebsiella pneumoniae ( K. pneumoniae ), as an important hospital-acquired bacterium, is responsible for severe morbidity and mortality among the elderly, newborn and immune-compromised people. We established a rcsA gene-based label-free multiple cross displacement amplification (MCDA) assay for rapid, simple and sensitive detection of K. pneumoniae by using lateral flow biosensor (LFB). MCDA reaction was conducted at a fixed temperature (65 °C) for only 30 min, and amplification results were directly indicated using LFB. The results showed that reaction products were detectable from as little as 100 fg and 4.8 CFU of pure K. pneumoniae templates, and from approximately 480 CFU in 1 mL of spiked clinical samples. All K. pneumoniae strains examined were positive for label-free MCDA-LFB analysis, and all non- K. pneumoniae strains used in the report were negative for label-free MCDA-LFB assay, indicating the high selectivity of the label free MCDA-LFB assay. Furthermore, to remove false-positive results, the label-free MCDA-LFB assay was supplemented with antarctic thermal sensitive uracil-DNA-glycosylase (AUDG) to eliminate the carryover contamination. Thus, label-free MCDA-LFB assay complemented with AUDG enzyme was a rapid, simple, sensitive and reliable technique for detection of target pathogen, which has the ability to effectively avoid carryover contamination, and can be a valuable tool for “on-site” detection, clinical diagnosis, and primary quarantine purposes.
-
multiple cross displacement amplification coupled with nanoparticles based lateral flow biosensor for detection of staphylococcus aureus and identification of methicillin resistant s aureus
Frontiers in Microbiology, 2018Co-Authors: Yi Wang, Weiqiang Yan, Yan WangAbstract:Staphylococcus aureus (S. aureus), including methicillin-resistant S. aureus (MRSA), is one of the most important human pathogens, which is responsible for bacteremia, soft-tissue infections, and food poisoning. Hence, multiple cross displacement amplification (MCDA) is employed to detect all S. aureus strains, and differentiates MRSA from methicillin-sensitive S. aureus. Multiplex MCDA (m-MCDA), which targets the nuc gene (S. aureus-specific gene) and mecA gene (encoding penicillin-binding protein-2'), could detect S. aureus strains and identify MRSA within 85 min. Detection of the m-MCDA products is achieved using disposable lateral flow biosensors. A total of 58 strains, including various species of Gram-positive and Gram-negative strains, are used for evaluating and optimizing m-MCDA assays. The optimal amplification condition is found to be 63°C for 40 min, with detection limits at 100 fg DNA/reaction for nuc and mecA genes in the pure cultures, and 10 CFU/tube for nuc and mecA genes in the blood samples. The analytical specificity of m-MCDA assay is of 100%, and no cross-reactions to non-S. aureus strains are produced according to the specificity testing. Particularly, two additional components, including AUDG enzyme and dUTP, are added into the m-MCDA amplification mixtures, which are used for eliminating the unwanted results arising from carryover contamination. Thus, the m-MCDA technique appears to be a simple, rapid, sensitive, and reliable assay to detect all S. aureus strains, and identify MRSA infection for appropriate antibiotic therapy.
-
development of multiple cross displacement amplification label based gold nanoparticles lateral flow biosensor for detection of listeria monocytogenes
International Journal of Nanomedicine, 2017Co-Authors: Yi Wang, Yan Wang, Lijuan LuoAbstract:Listeria monocytogenes, one of most problematic foodborne pathogens, is responsible for listeriosis in both humans and animals and mainly transmitted through the food chain. In this report, we propose a simple, rapid, and nearly instrument-free molecular technique using multiple cross displacement amplification (MCDA) label-based gold nanoparticles lateral flow biosensor (LFB) for specific, sensitive, and visual detection of L. monocytogenes. The MCDA-LFB method was carried out at a constant temperature (61°C) for only 20 min during the reaction stage, and then the amplification mixtures were directly detected by using LFB, eliminating the use of an electrophoresis instrument, special reagents, or amplicon analysis equipment. The whole procedure, from sample processing to result indicating, was finished within 1 h. The analytical specificity of MCDA-LFB method was successfully determined by distinguishing the target bacterium from other pathogens. The analytical sensitivity of the MCDA-LFB assay was 10 fg of genomic templates per reaction in pure culture, which was in complete accordance with MCDA by gel electrophoresis, real-time turbidity, and colorimetric indicator. The assay was also successfully applied to detecting L. monocytogenes in pork samples. Therefore, the rapidity, simplicity, and nearly equipment-free platform of the MCDA-LFB technique make it possible for food control, clinical diagnosis, and more. The proof-of-concept assay can be reconfigured to detect various target sequences by redesigning the specific MCDA primers.
-
multiplex rapid and sensitive isothermal detection of nucleic acid sequence by endonuclease restriction mediated real time multiple cross displacement amplification
Frontiers in Microbiology, 2016Co-Authors: Yi Wang, Yan Wang, Lijuan Luo, Lu Zhang, Dongxin Liu, Xiaolong Cao, Kai LiuAbstract:We have devised a novel isothermal amplification technology, termed endonuclease restriction-mediated real-time multiple cross displacement amplification (ET-MCDA), which facilitated multiplex, rapid, specific and sensitive detection of nucleic-acid sequences at a constant temperature. The ET-MCDA integrated multiple cross displacement amplification strategy, restriction endonuclease cleavage and real-time fluorescence detection technique. In the ET-MCDA system, the functional cross primer E-CP1 or E-CP2 was constructed by adding a short sequence at the 5’ end of CP1 or CP2, respectively, and the new E-CP1 or E-CP2 primer was labelled at the 5’ end with a fluorophore and in the middle with a dark quencher. The restriction endonuclease Nb.BsrDI specifically recognized the short sequence and digested the newly synthesized double-stranded terminal sequences (5’ end short sequences and their complementary sequences), which released the quenching, resulting on a gain of fluorescence signal. Thus, the ET-MCDA allowed real-time detection of single or multiple targets in only a single reaction, and the positive results were observed in as short as 12 minutes, detecting down to 3.125 fg of genomic DNA per tube. Moreover, the analytical specificity and the practical application of the ET-MCDA were also successfully evaluated in this study. Here we provided the details on the novel ET-MCDA technique and expounded the basic ET-MCDA amplification mechanism.